| Next 10 |
Ad
ANNX News and Press Annexon Inc.
News | Annexon Inc. (NASDAQ:ANNX)
-
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today anno...
-
2023-08-07 06:50:34 ET Annexon Biosciences press release ( NASDAQ: ANNX ): Q2 GAAP EPS of -$0.47 beats by $0.07 . Cash and cash equivalents and short-term investments were $192.9 million as of June 30, 2023. Based on the current operating plan, Annexon continues to exp...
-
ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with Geographic Atrophy; Company to Engage Regulatory Agencies to Determine Optimal Path Forward Multiple Key Catalysts Expected in Second Half 2023, Including Completion of Enrollment i...
-
2023-07-31 08:37:42 ET China Natural Resources ( NASDAQ: CHNR ) +49% . Allarity Therapeutics ( ALLR ) +31% . Barnes & Noble Education ( BNED ) +17% . Spero Therapeutics ( SPRO ) +13% Announces Special Protocol Assessment Agreement with FDA...
-
Additional analyses support consistent protection from vision loss Annexon to engage with regulatory agencies to determine optimal path forward for ANX007 Company to hold investor conference call on Monday, July 31, 2023, at 1:30 p.m. PT / 4:30 p.m. ET BRISBANE, Calif., Ju...
-
2023-07-28 17:39:07 ET Gainers: Annexon ( ANNX ) +5% . Fluence Energy ( FLNC ) +4% . Humacyte ( HUMA ) +3% . Stoke Therapeutics ( STOK ) +3% . Brightcove ( BCOV ) +3% . Losers: Silk Road Medical ( SILK ) -5% . ...
-
2023-07-28 14:00:40 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
-
BRISBANE, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthal...
-
BRISBANE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthal...
-
2023-07-14 19:21:21 ET Summary ANNX produced mixed results from its GA program. While the primary endpoint was not met, an important functional endpoint saw success. However, the market reaction was drastic, and perhaps too drastic. I covered Annexon ( ANNX ) in ...
Stock Information
Annexon Inc. Company Name:
ANNX Stock Symbol:
NASDAQ Market:
Ad
-
ANNX - Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference | Benzinga
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new cl...
-
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today anno...
-
ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with Geographic Atrophy; Company to Engage Regulatory Agencies to Determine Optimal Path Forward Multiple Key Catalysts Expected in Second Half 2023, Including Completion of Enrollment i...